Trulieve Cannabis Corp. (TRLV)
AI stock analysis · as of Jun 23, 2026
Loading microstructure…
Trulieve is the largest U.S. multi-state cannabis operator with a dominant ~162-store footprint in Florida, generating ~$1.18B in revenue with industry-leading 60% gross margins and meaningful FCF (~$212M). The core investment question is whether two binary regulatory catalysts — Florida adult-use legalization (Nov 2026 ballot) and federal rescheduling to Schedule III (eliminating the 280E tax burden) — materialize to unlock latent earnings power, or whether the stock remains a perpetually-discounted federally illegal operator hostage to political timing.
valuationMixed: EV/EBITDA of 7.7x and P/S of 1.4x look cheap, and a 12.6% FCF yield is compelling, but forward P/E of 34.7x and flat revenue growth temper the case — fair-to-cheap only if you underwrite at least one regulatory catalyst landing.
This analysis is from Jun 23, 2026. Want the latest on TRLV, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Genuine cash generation despite punitive 280E taxation: $212M FCF on $1.18B revenue implies a ~12.6% FCF yield at current market cap — rare in the MSO space
- · Florida 2026 adult-use ballot initiative would convert Trulieve's dominant medical network into the largest beneficiary of a multi-billion dollar rec market; FL is the majority of revenue
- · Trump executive order in December 2025 directing Schedule III rescheduling could eliminate 280E and structurally re-rate after-tax earnings — operating margin is already 12.4% but profit margin is -6.9% largely due to 280E
- · Historic NYSE uplist legitimizes the company and opens the door to institutional ownership (currently only ~11% institutional), a structural buyer base expansion
- · Operational scale advantages: 750,000 sq ft automated FL cultivation facility supports the 60% gross margin (best-in-class) and provides pricing flexibility against competitors
- · Debt refinancing extends maturities to 2030, removing near-term liquidity overhang; $255M cash provides runway
Bear case
- · Revenue is flat-to-declining (-0.4% YoY in 2025, -3.7% on TTM basis per key_metrics) — the growth story is entirely dependent on regulatory catalysts that may not materialize
- · CEO Kim Rivers and a 10% holder sold ~$4.53M of stock immediately following the NYSE uplist — a textbook negative insider signal at what insiders may view as peak optimism
- · Debt-to-equity of 54.8x is extreme; new notes carry a 10.5% coupon (up from 8.0%), increasing interest burden even as principal was reduced from $368M to $200M
- · Rohrbacher-Farr rider protecting medical operators was only extended through Jan 30, 2026 — annual political risk that traditional businesses don't face
- · Federal rescheduling has been 'imminent' for years; delays, court challenges, or partial implementation could disappoint a market that may be pricing in resolution
- · Net losses persisted three straight years (-$116M, -$155M, -$527M); even with 280E removed, the path to GAAP profitability requires execution, not just policy
Catalysts
- · Florida adult-use ballot initiative — November 2026 vote (requires 60% supermajority, which failed in 2024)
- · Federal Schedule III rescheduling finalization following December 2025 Trump executive order
- · Rohrbacher-Farr rider renewal by January 30, 2026 — near-term binary risk/relief
- · SAFER Banking Act passage, which would dramatically lower cost of capital
- · Q4 2025 / FY2025 earnings (next reported earnings 2026-08-06 per data, though quarterly cadence likely sooner)
- · Ohio adult-use ramp and Texas Compassionate Use license commercialization
Key risks
- · Florida 2026 ballot fails again to clear 60% threshold — the single most important growth lever evaporates
- · Schedule III rescheduling stalls in administrative review or is blocked by litigation, perpetuating 280E
- · Continued revenue stagnation/decline as competition and intoxicating hemp products erode pricing
- · Leverage stress if FCF compresses; 10.5% coupon on new notes is expensive capital
- · Insider selling continues, signaling management's own valuation skepticism
What to watch
- · Rohrbacher-Farr rider renewal status by Jan 30, 2026
- · Concrete DEA/administrative progress on Schedule III rescheduling timeline
- · Florida 2026 ballot polling and signature certification progress
- · Next earnings release — watch revenue trajectory, FCF durability, and 2026 guidance
- · Further insider transactions from Rivers and the 10% holder
- · Technical levels: 52-week low $3.25 as bear support, $13.28 high as upside resistance
Key metrics
Price target rationale
Base $10: ~8.5x EV/EBITDA on roughly flat fundamentals, modest re-rating from NYSE uplist and institutional inflows. Bull $18: 280E relief lifts after-tax FCF materially and FL adult-use optionality is priced in, ~12x EV/EBITDA. Bear $4.5: FL ballot fails, rescheduling delayed, leverage and 280E continue to suppress earnings — reverts toward 52-week-low range and ~4-5x EV/EBITDA.
On Wall Street's view (mixed): The lone $21 sell-side target implies ~150% upside and likely reflects a full rescheduling + Florida rec scenario, which is plausible but binary; we think a base case sits well below that, though the bull-case math can support it if both catalysts hit.
Latest filing (10-K)
Trulieve is the US cannabis retail market leader betting heavily on Florida adult-use legalization and federal rescheduling to unlock its dominant store network and eliminate the punishing 280E tax burden that suppresses its GAAP earnings.
Trulieve Cannabis Corp. is a vertically integrated, multi-state cannabis operator headquartered in Tallahassee, Florida. It cultivates, manufactures, and retails cannabis products through 233 dispensaries across nine states (FL, AZ, PA, WV, OH, GA, MD, CT, CO), making it the largest cannabis retailer in the US by store count. Revenue is generated primarily through retail dispensary sales, with a smaller wholesale component. Florida, with 162 dispensaries, is the dominant market and remains medical-only.
What the news says · bullish
The dominant storyline is Trulieve's historic uplist to the NYSE — the first U.S. plant-touching cannabis company to achieve this — which has generated meaningful positive coverage and a valuation argument that the stock may be significantly undervalued post-listing. The move is seen as a legitimizing catalyst for both Trulieve and the broader cannabis sector, potentially unlocking institutional capital. However, two notable headwinds temper enthusiasm: CEO Kim Rivers and a 10% shareholder sold a combined ~$4.53M in shares shortly after the listing, a classic insider-selling red flag. The company is also described as only 'on the verge of breaking even,' suggesting the fundamental earnings story remains unproven. Jim Cramer's endorsement as a 'terrific spec' underscores the speculative nature of the investment.
This analysis is from Jun 23, 2026. Markets move. Get the current read on TRLV and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.